LBTD (Lotus Bio-Technology Development) Equity-to-Asset: -1.11 (As of Dec. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lotus Bio-Technology Development Equity-to-Asset?

Lotus Bio-Technology Development LBTD -99.99% Equity-to-Asset is -1.11 as of Dec. 2017.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lotus Bio-Technology Development's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $-0.06 Mil. Lotus Bio-Technology Development's Total Assets for the quarter that ended in Dec. 2017 was $0.06 Mil.

The historical rank and industry rank for Lotus Bio-Technology Development's Equity-to-Asset or its related term are showing as below:

LBTD's Equity-to-Asset is not ranked *
in the Agriculture industry.
Industry Median: 0.53
* Ranked among companies with meaningful Equity-to-Asset only.

Lotus Bio-Technology Development  (OTCPK:LBTD) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Lotus Bio-Technology Development Equity-to-Asset Related Terms

Lotus Bio-Technology Development Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Lotus Bio-Technology Development's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Bio-Technology Development Equity-to-Asset Chart

Lotus Bio-Technology Development Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17
Equity-to-Asset
Get a 7-Day Free Trial -2.25 0.00 -22.50 -12.20 0.00

Lotus Bio-Technology Development Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.00 0.00 0.00 0.00 -1.11

LBTD vs SNES, CVAT: Equity-to-Asset Comparison

For the Agricultural Inputs subindustry, Lotus Bio-Technology Development's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lotus Bio-Technology Development Equity-to-Asset vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Lotus Bio-Technology Development's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lotus Bio-Technology Development's Equity-to-Asset falls into.


Lotus Bio-Technology Development Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lotus Bio-Technology Development's Equity to Asset Ratio for the fiscal year that ended in Mar. 2017 is calculated as

Equity to Asset (A: Mar. 2017 )=Total Stockholders Equity/Total Assets
=-0.081/0
=

Lotus Bio-Technology Development's Equity to Asset Ratio for the quarter that ended in Dec. 2017 is calculated as

Equity to Asset (Q: Dec. 2017 )=Total Stockholders Equity/Total Assets
=-0.061/0.055
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -1.11 mean?
Lotus Bio-Technology Development (LBTD) has a Equity-to-Asset of -1.11 as of Dec. 2017. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lotus Bio-Technology Development and its competitors.
Is Lotus Bio-Technology Development's Equity-to-Asset too high?
Lotus Bio-Technology Development's current Equity-to-Asset is -1.11.
How does Lotus Bio-Technology Development's Equity-to-Asset compare to SNES and CVAT?
Lotus Bio-Technology Development's Equity-to-Asset of -1.11 can be compared against companies in the Agriculture industry. The industry median Equity-to-Asset is 0.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Agriculture company?
The median Equity-to-Asset among Agriculture companies is 0.53, based on 258 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lotus Bio-Technology Development and its competitors. For the Agriculture industry, the median Equity-to-Asset is 0.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Bio-Technology Development's current Equity-to-Asset is -1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Bio-Technology Development stock overvalued right now?
Lotus Bio-Technology Development (LBTD) has a current Equity-to-Asset of -1.11. The current Equity-to-Asset is -1.11. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lotus Bio-Technology Development (LBTD), the current Equity-to-Asset is -1.11 as of Dec. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lotus Bio-Technology Development Business Description

Address 108 2559 Parkview Lane, Port Coquitlam, BC, CAN, V3C6M1
Lotus Bio-Technology Development Corp is actively seeking out new opportunities in the Organic and Bio-technology space.